Literature DB >> 16821025

Nephrogenic fibrosing dermopathy in children.

Ari Auron1, Lei Shao, Bradley A Warady.   

Abstract

Nephrogenic fibrosing dermopathy (NFD) is an entity of unknown etiology that has only been reported in patients with impaired kidney function. It has characteristic diagnostic findings by skin biopsy and due to its systemic involvement in some reported cases, the term "nephrogenic systemic fibrosis" has been recently suggested as more appropriate for the nomenclature of this entity. There is no curative treatment currently available and very few cases have been reported in children. We hereby report two cases so as to alert pediatric health care providers about the existence of this disorder.

Entities:  

Mesh:

Year:  2006        PMID: 16821025     DOI: 10.1007/s00467-006-0174-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  24 in total

1.  Scleromyxoedema-like changes in four renal dialysis patients.

Authors:  V Hubbard; A Davenport; M Jarmulowicz; M Rustin
Journal:  Br J Dermatol       Date:  2003-03       Impact factor: 9.302

2.  UV-A1 phototherapy improves nephrogenic fibrosing dermopathy.

Authors:  Reza Kafi; Gary J Fisher; Taihao Quan; Yuan Shao; Rui Wang; John J Voorhees; Sewon Kang
Journal:  Arch Dermatol       Date:  2004-11

3.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin.

Authors:  Samuel L Moschella; Jonathan Kay; Bonnie T Mackool; Vincent Liu
Journal:  N Engl J Med       Date:  2004-11-18       Impact factor: 91.245

Review 4.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review.

Authors:  Sumanth R Daram; Cherise M Cortese; Bahar Bastani
Journal:  Am J Kidney Dis       Date:  2005-10       Impact factor: 8.860

5.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

6.  Nephrogenic fibrosing dermopathy.

Authors:  T Gambichler; V Paech; A Kreuter; M Wilmert; P Altmeyer; M Stücker
Journal:  Clin Exp Dermatol       Date:  2004-05       Impact factor: 3.470

7.  Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis.

Authors:  Pedro W Baron; Kenneth Cantos; Donald J Hillebrand; Ke-Qin Hu; Okechukwu N Ojogho; Sandra Nehlsen-Cannarella; Waldo Concepcion
Journal:  Am J Dermatopathol       Date:  2003-06       Impact factor: 1.533

8.  Thalidomide is an inhibitor of angiogenesis.

Authors:  R J D'Amato; M S Loughnan; E Flynn; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).

Authors:  Julian M Mackay-Wiggan; David J Cohen; Mark A Hardy; Elizabeth H Knobler; Marc E Grossman
Journal:  J Am Acad Dermatol       Date:  2003-01       Impact factor: 11.527

10.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Authors:  E P Sampaio; E N Sarno; R Galilly; Z A Cohn; G Kaplan
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

2.  Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report.

Authors:  Beatrice Nardone; Elise Saddleton; Anne E Laumann; Beatrice J Edwards; Dennis W Raisch; June M McKoy; Steven M Belknap; Christian Bull; Anand Haryani; Shawn E Cowper; Ali K Abu-Alfa; Frank H Miller; Victoria Godinez-Puig; Vikas R Dharnidharka; Dennis P West
Journal:  Pediatr Radiol       Date:  2013-09-21

3.  MR urography in children. Part 1: how we do the F0 technique.

Authors:  Pierre-Hugues Vivier; Michael Dolores; Melissa Taylor; Frederic Elbaz; Agnes Liard; Jean-Nicolas Dacher
Journal:  Pediatr Radiol       Date:  2010-02-25

4.  Non-enhanced ECG-gated respiratory-triggered 3-D steady-state free-precession MR angiography with slab-selective inversion: initial experience in visualisation of renal arteries in free-breathing children without renal artery abnormality.

Authors:  Dirk Klee; Rotem Shlomo Lanzman; Dirk Blondin; Peter Schmitt; Jun Oh; Burak Salgin; Ertan Mayatepek; Gerald Antoch; Jörg Schaper
Journal:  Pediatr Radiol       Date:  2012-03-31

Review 5.  Recent advances in pediatric dialysis: a review of selected articles.

Authors:  John D Mahan; Hiren P Patel
Journal:  Pediatr Nephrol       Date:  2008-06-12       Impact factor: 3.714

Review 6.  Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.

Authors:  Jeffrey G Penfield
Journal:  Pediatr Nephrol       Date:  2008-06-10       Impact factor: 3.714

Review 7.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

Review 8.  Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity.

Authors:  Derrick J Todd; Jonathan Kay
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

9.  [Nephrogenic systemic fibrosis: a rare disease with grave consequences].

Authors:  J T Kielstein; M Schiffer
Journal:  Internist (Berl)       Date:  2010-01       Impact factor: 0.743

Review 10.  Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance.

Authors:  Theresa Reiter; Oliver Ritter; Martin R Prince; Peter Nordbeck; Christoph Wanner; Eike Nagel; Wolfgang Rudolf Bauer
Journal:  J Cardiovasc Magn Reson       Date:  2012-05-20       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.